Skip to main content

Table 4 Effects of the de-implementation strategy, measurement, and covariates on the outcome “use of EPO” in EPO eligible patients (Hb <13 g/dL)

From: The effectiveness of a de-implementation strategy to reduce low-value blood management techniques in primary hip and knee arthroplasty: a pragmatic cluster-randomized controlled trial

  OR 95% CI p value
Intervention group, relative to control group 1.3 0.3 to 6.8 0.73
Time effect, effect measurement relative baseline 0.3 0.1 to 0.9 0.043
Joint, knee relative to hip 0.9 0.6 to 1.3 0.60
Sex, female relative to male 1.2 0.7 to 2.1 0.50
ASA classification, relative to 1
• ASA 2 1.0 0.5 to 1.7 0.88
• ASA 3–4 0.5 0.3 to 1.1 0.07
BMI 1.0 1.0 to 1.0 0.42
Preoperative Hb 0.3 0.2 to 0.4 <0001
Age 1.0 1.0 to 1.0 0.97